Effect of Prophylactic Post-transplant Ponatinib Administration on Outcomes in Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

The effect of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia has remained unknown. The presented results suggest that survival in the ponatinib group was better than that in the non –ponatinib group and that ponatinib maintenance therapy is safe. The post-transplant ponatinib maintenance strategy might be promising.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2020 Category: Hematology Authors: Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae Tags: Original Study Source Type: research